A number of studies have shown that peptide agonists of the glucagon-like peptide 1 receptor (GLP1-R), which are licensed for the treatment of type 2 diabetes mellitus (T2DM), also have potent neuroprotective and anti-inflammatory properties (Liu et al, 2015; Zhang et al, 2019). Here, GLP1R is linked to type 2 diabetes mellitus.